These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 8917194)
1. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma. Brandau W; Niehoff T; Pulawski P; Jonas M; Dutschka K; Sciuk J; Coenen HH; Schober O J Nucl Med; 1996 Nov; 37(11):1865-71. PubMed ID: 8917194 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of iodine-123-IMBA for melanoma imaging. Nicholl C; Mohammed A; Hull WE; Bubeck B; Eisenhut M J Nucl Med; 1997 Jan; 38(1):127-33. PubMed ID: 8998166 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. Michelot JM; Moreau MF; Labarre PG; Madelmont JC; Veyre AJ; Papon JM; Parry DF; Bonafous JF; Boire JY; Desplanches GG J Nucl Med; 1991 Aug; 32(8):1573-80. PubMed ID: 1869982 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, radiolabeling, and preliminary evaluation in mice of some (N-diethylaminoethyl)-4-iodobenzamide derivatives as melanoma imaging agents. Moreau MF; Michelot J; Papon J; Bayle M; Labarre P; Madelmont JC; Parry D; Boire JY; Moins N; Seguin H Nucl Med Biol; 1995 Aug; 22(6):737-47. PubMed ID: 8535334 [TBL] [Abstract][Full Text] [Related]
6. N-(2-diethylaminoethyl)-4-[123I]iodobenzamide as a tracer for the detection of malignant melanoma: simple synthesis, improved labelling technique and first clinical results. Brandau W; Kirchner B; Bartenstein P; Sciuk J; Kamanabrou D; Schober O Eur J Nucl Med; 1993 Mar; 20(3):238-43. PubMed ID: 8462613 [TBL] [Abstract][Full Text] [Related]
7. Preparation and biologic evaluation of a novel radioiodinated benzylpiperazine, 123I-MEL037, for malignant melanoma. Pham TQ; Berghofer P; Liu X; Greguric I; Dikic B; Ballantyne P; Mattner F; Nguyen V; Loc'h C; Katsifis A J Nucl Med; 2007 Aug; 48(8):1348-56. PubMed ID: 17631542 [TBL] [Abstract][Full Text] [Related]
8. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide. John CS; Bowen WD; Saga T; Kinuya S; Vilner BJ; Baumgold J; Paik CH; Reba RC; Neumann RD; Varma VM J Nucl Med; 1993 Dec; 34(12):2169-75. PubMed ID: 8254405 [TBL] [Abstract][Full Text] [Related]
9. [Diagnostic value of 123iodine-ibzm scintigraphy for staging of malignant melanomas]. Henker C; Bida B; Markwardt J; Schlag P Nuklearmedizin; 1997 Jan; 36(1):1-6. PubMed ID: 9082335 [TBL] [Abstract][Full Text] [Related]
10. Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl ] benzamide whole-body scintigraphy in patients with malignant melanoma: a comparison with thallium-201 imaging. Brenner W; Klomp HJ; Bohuslavizki KH; Szonn B; Kampen WU; Henze E Eur J Nucl Med; 1999 Dec; 26(12):1567-71. PubMed ID: 10638408 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Moins N; Papon J; Seguin H; Gardette D; Moreau MF; Labarre P; Bayle M; Michelot J; Gramain JC; Madelmont JC; Veyre A Nucl Med Biol; 2001 Oct; 28(7):799-808. PubMed ID: 11578901 [TBL] [Abstract][Full Text] [Related]
12. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. Larisch R; Schulte KW; Vosberg H; Ruzicka T; Müller-Gärtner HW J Nucl Med; 1998 Jun; 39(6):996-1001. PubMed ID: 9627332 [TBL] [Abstract][Full Text] [Related]
13. [Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma]. Sillaire-Houtmann I; Bonafous J; Veyre A; Mestas D; D'Incan M; Moins N; Kemeny JL; Chossat F; Bacin F J Fr Ophtalmol; 2004 Jan; 27(1):34-9. PubMed ID: 14968075 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. Pham TQ; Greguric I; Liu X; Berghofer P; Ballantyne P; Chapman J; Mattner F; Dikic B; Jackson T; Loc'h C; Katsifis A J Med Chem; 2007 Jul; 50(15):3561-72. PubMed ID: 17602544 [TBL] [Abstract][Full Text] [Related]
15. In vitro studies on the cellular uptake of melanoma imaging aminoalkyl-iodobenzamide derivatives (ABA). Dittmann H; Coenen HH; Zölzer F; Dutschka K; Brandau W; Streffer C Nucl Med Biol; 1999 Jan; 26(1):51-6. PubMed ID: 10096501 [TBL] [Abstract][Full Text] [Related]
16. Examination of four 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents: initial studies in mouse tumor models. Waterhouse RN; Chapman J; Izard B; Donald A; Belbin K; O'Brien JC; Collier TL Nucl Med Biol; 1997 Aug; 24(6):587-93. PubMed ID: 9316089 [TBL] [Abstract][Full Text] [Related]
18. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). Michelot JM; Moreau MF; Veyre AJ; Bonafous JF; Bacin FJ; Madelmont JC; Bussiere F; Souteyrand PA; Mauclaire LP; Chossat FM J Nucl Med; 1993 Aug; 34(8):1260-6. PubMed ID: 8326382 [TBL] [Abstract][Full Text] [Related]
19. [Perspectives of scintigraphic diagnosis of malignant lymphoma using a new radiopharmaceutical]. Meyniel G; Michelot J; Moreau MF; Veyre A C R Acad Sci III; 1990; 311(1):13-8. PubMed ID: 2125523 [TBL] [Abstract][Full Text] [Related]
20. Iodide benzamides for the in-vivo detection of melanoma and metastases. Edreira MM; Pozzi OR Melanoma Res; 2006 Feb; 16(1):37-43. PubMed ID: 16432454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]